Canada cell therapy manufacturing market is
anticipated to witness impressive growth during the forecast period. This can
be ascribed to the high prevalence of cancer and other target diseases and
increasing R&D investments in pharmaceutical companies across the region.
Similarly, increasing number of clinical trials and approval of stem cell-based
therapies from regulatory bodies will further drive the growth of the Canada
cell therapy manufacturing market during the forecast period. Also, growing
financial assistance from governments, private vendors, and NGOs are
anticipated to propel the growth of the Canada cell therapy manufacturing
market during the forecast period. Manufacturers are involved in developing and
launching various types of technologies for cell therapy manufacturing, which
will further propel the growth of the Canada cell therapy manufacturing market
during the forecast period.
Increasing Prevalence of Chronic Diseases
The increasing prevalence of chronic diseases is a
major driver for the growth of the Canada cell therapy manufacturing market.
Chronic diseases such as cancer, diabetes, cardiovascular diseases, and
neurological disorders are among the leading causes of death and disability
across the world. Traditional treatments for these diseases, such as
chemotherapy, radiation therapy, and surgery, have limitations and may not
always be effective. As a result, there is a growing interest in cell-based
therapies that offer the potential for more targeted and effective treatments.
Cell therapies are a promising new approach to treating chronic diseases. They
involve using living cells to replace or repair damaged or diseased cells in
the body. Cell therapies have shown promising results in treating a variety of
conditions, including cancer, heart disease, and neurological disorders. As
such, the increasing prevalence of chronic diseases has created a growing
demand for cell-based therapies. In Canada, the increasing prevalence of
chronic diseases has led to a greater focus on developing innovative cell-based
therapies. Canadian researchers and companies are actively working to develop
new cell therapies and are making significant progress in this area. The
Canadian government is also investing in research and development to support
the growth of the cell therapy industry.
Supportive Government Policies
Supportive government policies are a key driver for
the growth of the Canada cell therapy manufacturing market. The government
provides funding for research and development in the field of cell therapy.
This funding supports basic and applied research that is focused on developing
new cell-based therapies and advancing existing ones. The government offers tax
incentives for companies that invest in research and development, as well as
those that invest in the production and commercialization of cell-based
therapies. These incentives help to reduce the costs of developing and
manufacturing these therapies. The government offers grants and funding to
startups and small businesses that are focused on developing cell-based
therapies. This support helps to reduce the barriers to entry for smaller
companies and encourages innovation in the industry. The government is
investing in infrastructure and workforce development to support the growth of
the cell therapy industry. This includes funding for research facilities,
manufacturing facilities, and training programs for workers in the industry.
Technological Advancements
Technological advancements are a major driver for the
growth of the Canada cell therapy manufacturing market. Advances in cell
biology, genetics, and engineering have paved the way for the development of
new and innovative cell-based therapies that will drive the growth of the
market during the forecast period. Technological advancements have led to a
better understanding of how cells work and how they can be used to treat
diseases. This has paved the way for the development of new and innovative cell-based
therapies that are more effective and have fewer side effects than traditional
treatments. Gene editing and gene therapy are emerging as promising new
approaches to treat diseases. These technologies enable researchers to modify
the genetic material of cells to correct genetic defects or enhance their
therapeutic potential. Technological advancements have led to the development
of new manufacturing processes for cell-based therapies. These processes are
more efficient, scalable, and cost-effective than traditional manufacturing
methods, making it easier to produce cell-based therapies at a commercial
scale. Automation and robotics are being integrated into the cell therapy
manufacturing process, improving the efficiency and reliability of the manufacturing
process. This has led to reduced costs, faster production times, and improved
quality control.
Research and Development
Research and development (R&D) are key drivers of
the growth of the Canada cell therapy manufacturing market. The development of
new and innovative cell-based therapies requires significant investment in
R&D to discover and develop new therapies, optimize manufacturing processes,
and demonstrate safety and efficacy through clinical trials. R&D is driving
the development of new cell therapies that can be used to treat a wide range of
diseases, including cancer, heart disease, and neurological disorders. This
includes the identification and characterization of new cell types, as well as
the development of new technologies for manipulating and engineering cells.
R&D is also focused on optimizing manufacturing processes to improve the
efficiency, scalability, and cost-effectiveness of cell therapy production.
This includes the development of new technologies for culturing and expanding
cells, as well as the integration of automation and robotics to streamline the
manufacturing process. R&D is also critical for demonstrating the safety
and efficacy of cell-based therapies through clinical trials. These trials are
necessary to obtain regulatory approval and to bring new therapies to market.
R&D is often conducted through collaboration and partnerships between
academia, industry, and government. These collaborations bring together
expertise from different fields and help to accelerate the development of new
therapies and technologies.
Growing Demand for Personalized Medicines
The growing demand for personalized medicines is a key
driver for the growth of the Canada cell therapy manufacturing market.
Personalized medicine refers to the use of a patient's genetic information,
lifestyle, and other factors to tailor treatments to their individual needs.
Cell-based therapies are particularly well-suited for personalized medicine
because they can be customized to a patient's specific condition and genetic
profile. Cell-based therapies can be tailored to a patient's specific condition
and genetic profile, making them ideal for personalized medicines. Advances in
cell biology, gene editing, and other technologies are making it possible to
develop patient-specific therapies that are more effective and have fewer side
effects than traditional treatments. Precision medicine is an approach to
healthcare that emphasizes the customization of treatments to individual
patients. Cell-based therapies are an important component of precision
medicine, and the growing demand for personalized medicine is driving increased
investment in this area. The growing demand for personalized medicine is
driving the expansion of cell therapy applications beyond traditional areas
such as cancer and blood disorders. Cell-based therapies are being developed
for a wide range of conditions, including autoimmune diseases, neurological disorders,
and cardiovascular disease. The demand for personalized medicine is also
driving changes in regulatory and reimbursement policies. Regulators and payers
are increasingly recognizing the value of personalized medicine and are working
to create a regulatory and reimbursement framework that supports the
development and commercialization of these therapies.
Recent Development
- In January 2022, STEMCELL Technologies announced
the opening of a new 66,000 square-foot manufacturing facility in Burnaby,
British Columbia. The facility will produce cell therapy products for
clinical trials and commercial use and will support the development of
stem cell-based therapies for a range of conditions.
- In November 2021, the Center for
Commercialization of Regenerative Medicine (CCRM) and CCRM Australia
announced a partnership to provide manufacturing services for CAR-T cell
therapies. The partnership will leverage the manufacturing expertise of
both organizations to support the development and commercialization of cell-based
therapies in Canada and Australia.
- In September 2021, Avicanna Inc. and University
Health Network announced a collaboration to develop and manufacture neural
stem cell-based therapies for neurological disorders. The partnership will
leverage Avicanna's expertise in cannabis-based therapies and the
University Health Network's expertise in cell-based therapies to advance
the development of new treatments.
- In August 2021, the Government of Canada
announced $25 million in funding for the Center for Commercialization of
Regenerative Medicine (CCRM) to support the development and
commercialization of cell-based therapies. The funding will support the
establishment of a new manufacturing facility in Toronto, as well as the
development of new cell therapies for a range of conditions.
Download Free Sample Report
Market Segmentation
The Canada cell therapy manufacturing market can be
segmented by therapy, source of cell, source, application, end user, and
region. Based on therapy, the Canada cell therapy manufacturing market can be
segmented into T-Cell therapies, dendritic cell therapies, tumor cell
therapies, and stem cell therapies. Based on source of cell, the Canada cell
therapy manufacturing market can be divided into autologous v/s allogenic.
Based on source, the Canada cell therapy manufacturing market can be divided
into in-house v/s contract manufacturing. Based on application, the Canada cell
therapy manufacturing market can be segmented into oncology, cardiovascular
diseases, orthopedic diseases, and others. Based on end user, the Canada cell
therapy manufacturing market can be grouped into pharmaceutical &
biotechnology companies, academic & research institutes, and others.
Market Players
Novartis Pharmaceuticals Canada Inc, Hoffmann-La Roche
Ltd., Gilead Sciences Inc, Thermo Fisher Scientific Inc, Catalent Ontario Ltd.,
Takeda Canada Inc., and Amgen Canada Inc. are some of the leading players
operating in the Canada cell therapy manufacturing market.
|
Attribute
|
Details
|
|
Base
Year
|
2022
|
|
Historic
Data
|
2018 – 2021
|
|
Estimated
Year
|
2023
|
|
Forecast
Period
|
2024 – 2028
|
|
Quantitative
Units
|
Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028
|
|
Report
Coverage
|
Revenue
forecast, company share, competitive landscape, growth factors, and trends
|
|
Segments
Covered
|
By Therapy
By Source of
Cell
By Source
By Application
By End User
By Region
|
|
Regional
scope
|
Ontario
region; Quebec region; Alberta region; British Columbia region; Saskatchewan
and Manitoba region; Rest of Canada
|
|
Key
companies profiled
|
Novartis
Pharmaceuticals Canada Inc, Hoffmann-La Roche Ltd., Gilead Sciences Inc,
Thermo Fisher Scientific Inc, Catalent Ontario Ltd., Takeda Canada Inc.,
Amgen Canada Inc.
|
|
Customization
scope
|
10%
free report customization with purchase. Addition or alteration to country,
regional & segment scope.
|
|
Pricing
and purchase options
|
Avail customized purchase options to meet your exact research
needs. Explore purchase options
|
|
Delivery
Format
|
PDF and Excel through Email (We can also provide the editable
version of the report in PPT/Word format on special request)
|
Report Scope:
In this report, the Canada cell therapy manufacturing market has been
segmented into the following categories, in addition to the industry trends
which have also been detailed below:
·
Canada Cell Therapy Manufacturing Market, By Therapy:
o
T-Cell Therapies
o
Dendritic Cell Therapies
o
Tumor Cell Therapies
o
Stem Cell Therapies
·
Canada Cell Therapy Manufacturing Market, By Source of
Cell:
o
Autologous
o
Allogenic
·
Canada Cell Therapy Manufacturing Market, By Source:
o
In-House
o
Contract Manufacturing
·
Canada Cell Therapy Manufacturing Market, By
Application:
o
Oncology
o
Cardiovascular Diseases
o
Orthopedic Diseases
o
Others
·
Canada Cell Therapy Manufacturing Market, By End User:
o
Pharmaceutical & Biotechnology Companies
o
Academic & Research Institutes
o
Others
·
Canada Cell Therapy Manufacturing Market, By Region:
o
Ontario region
o
Quebec region
o
Alberta region
o
British Columbia region
o
Saskatchewan and Manitoba region
o
Rest of Canada
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present
in the Canada cell therapy manufacturing market.
Available Customizations:
With the given market data, TechSci Research offers customizations
according to a company’s specific needs. The following customization options
are available for the report:
Company Information
- Detailed
analysis and profiling of additional market players (up to five).
Canada cell therapy manufacturing market is an upcoming report to be
released soon. If you wish an early delivery of this report or want to confirm
the date of release, please contact us at [email protected]